financetom
META
financetom
/
Communication Services
/
META
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Meta Platforms, Inc.META
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide.

It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately.

The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere.

The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021.

Meta Platforms, Inc. was incorporated in 2004 and is headquartered in Menlo Park, California.

Latest News >
Genenta Science Receives Regulatory Approval in Italy for Phase 1 Temferon Trial
Genenta Science Receives Regulatory Approval in Italy for Phase 1 Temferon Trial
Oct 2, 2024
07:05 AM EDT, 10/02/2024 (MT Newswires) -- Genenta Science (GNTA) said Wednesday it received approval from the Italian Medicines Agency for a phase 1 clinical trial evaluating the company's drug Temferon in treating metastatic renal cell cancer. The trial is expected to commence in Q4, Genenta said. It will target patients with a median overall survival that is currently less...
London's Canary Wharf sets sights on hotels to fill empty offices
London's Canary Wharf sets sights on hotels to fill empty offices
Oct 2, 2024
* Canary Wharf mulling approaches from 30-plus hotel operators * Close to deal with 74-bed boutique hotel * Landlord has faced tough time, with falling office demand (Adds office vacancy data in paragraph 3, graphic) By Iain Withers LONDON, Oct 2 (Reuters) - London's Canary Wharf financial district wants to convert swathes of empty office space into other uses including...
US fund association picks new board as risks loom of higher tax, new regulations
US fund association picks new board as risks loom of higher tax, new regulations
Oct 2, 2024
NEW YORK (Reuters) - The Managed Funds Association, an alternative asset management trade group, announced on Wednesday its new board of directors, as well as its chair Jody Gunderson, managing principal at $16 billion credit investment firm AB CarVal, as the industry prepares for the threat of higher taxes and new regulation. The new team comes as the advocacy group...
Vera Therapeutics Expands Development of Kidney Disease Drug Pipeline
Vera Therapeutics Expands Development of Kidney Disease Drug Pipeline
Oct 2, 2024
07:08 AM EDT, 10/02/2024 (MT Newswires) -- Vera Therapeutics ( VERA ) said Wednesday that it would expand the development of its lead asset, atacicept, following positive results from the ongoing phase 2 and 3 trials in patients with IgA nephropathy and other autoimmune kidney indications. The company said it plans to initiate a study in Q4 to give its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved